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Abstract
Background: Patients with New World cutaneous leishmaniasis (NWCL) caused by Leishmania Viannia are treated with
parenteral sodium stibogluconate (SbV) to reduce the risk of development of mucocutanous leishmaniasis. Our centre
manages patients with NWCL on an outpatient-basis. This study was conducted to assess the safety and efficacy of this
approach.
Methodology: We reviewed records of 67 consecutive NWCL patients, aged 17–61 years, treated as day-cases with 20 mg/
kg/day SbV for up to 28 days at our UK centre. Data had been collected in a standardised format at the time of treatment
using a care-record tool. Patients reported adverse-effects daily using a structured questionnaire. Blood tests and
electrocardiograms were performed twice weekly to monitor for toxicity.
Principal Findings: Parenteral SbV treatment was associated with an early, significant suppression of mean lymphocyte and
platelet counts. By day four of treatment, lymphocytes reduced by 0.53610
9/L (CI 0.29610
9/L to 0.76610
9/L, p,0.001), and
platelets by 31,000/mL (CI 16,000/mL to 46,000/mL, p,0.001). SbV was further associated with significant elevation of serum
alanine transaminase concentrations, with a mean peak rise of 107 iu/L by day 13 (CI 52 iu/L to 161 iu/L, p,0.001). These
disturbances were temporary and did not result in adverse clinical events. Patient-described symptoms were cumulative
and at three weeks of treatment, 59.6% of patients experienced myalgia and 29.8% malaise. Treatment adherence and
clinical outcomes were comparable to inpatient treatment studies. A total of 1407 individual doses of SbV resulted in only
26 nights’ hospital admission, a saving of 1381 bed-days compared to inpatient treatment.
Conclusions/Significance: In specialist centres, NWCL patients aged below 65 years and without co-morbidities can be
safely and effectively treated without hospital admission. This reduces the cost of treatment, and is much preferred by
patients. Twice weekly blood and electrocardiographic monitoring may be surplus to requirement in clinically well, low-risk
patients.
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Introduction
Cutaneous leishmaniasis (CL) develops after inoculation of the
skin with protozoan parasites of the genus Leishmania, transmitted
by the bite of phlebotomine sandflies. Cutaneous nodules form
and then ulcerate, typically within weeks of initial infection. The
annual worldwide incidence of CL is estimated at 1–1.5 million
cases, with over 90% of cases occurring in the Middle East and
South America [1]. CL may be classified by the geographical
origin of the parasite, and New World cutaneous leishmaniasis
(NWCL) describes CL endemic to Central and South America,
most frequently caused by L.viannia and L.mexicana complex.
Infection with L.viannia can be complicated by mucocutanoeus
leishmaniasis (MCL), when parasites spread to the nasopharyngeal
mucosa and produce local destruction [2]. Among indigenous
people in rural Bolivia, untreated CL was estimated to progress to
MCL in an estimated 5–20% of patients [3]. At the Hospital for
Tropical Diseases, London, UK (HTD) between 1995 and 2003
we saw 81 cases of active or healed L.viannia NWCL, six of which
were complicated by MCL [4]. MCL does not heal spontaneously,
is disfiguring and can be fatal. It is important to identify the
subgenus of the infecting organism of a NWCL lesion, as
parenteral treatment is required in all cases of L.viannia to reduce
the risk of developing MCL. Parenteral therapy is also recom-
mended when it is not possible to identify the NWCL species or in
‘complicated’ L.mexicana complex infections (where there are
multiple or large lesions, lesions involve the face or a joint, or
there is involvement of the lymphatic system), to aid primary lesion
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New World and Old World) should self-heal without dissemina-
tion. However, parenteral, intra-muscular or intra-lesional penta-
valent antimonials are still recommended as first line treatment in
this instance, to accelerate cure and to reduce scarring [2].
The World Health Organisation and the Centres for Disease
Control recommend a course of 20 mg/kg/day of sodium
stibogluconate (SbV) for 20 days to treat NWCL caused by
L.viannia [6–12]. The administration of SbV is associated with
transient toxicities, which have been previously characterized.
However, many of the reports on SbV toxicity were published
more than 20 years ago or have limitations. In 2011, Oliveira et al
published the first systematic review on the adverse effects of
treatments for NWCL and approved only 65 studies on
pentavalent antimonials for NWCL as suitable for inclusion, with
a total of only 937 patients treated in clinical trials. Furthermore,
disparity between treatment regimens employed by different
centres, the variability in the antimonium content in each batch
of drug produced and a paucity of quantifiable data meant few
firm conclusions could be drawn [13].
Patient-described side effects are cumulative and dose-related. A
1998 study of 96 military personnel with NWCL treated with the
standard regime reported mylagia in 55%, fatigue in 39%,
abdominal pain in 29% and nausea and vomiting in 27% [14].
SbV administration is associated with bone marrow suppres-
sion. Hepburn described transient thrombocytopaenia complicat-
ing a case of NWCL after standard SbV treatment [15].
Wortmann et al published a prospective study in 1997 of eight
NWCL patients in which the white cell and lymphocyte counts
were demonstrated to have decreased on day seven of standard
SbV treatment [16]. There are case reports of cutaneous and
meningitic varicella zoster virus infection during treatment, which
have been attributed to SbV-induced leucopenia [16–18].
Standard SbV treatment for NWCL is known to derange liver
function. Lawn et al demonstrated that in 65 patients, 85%
developed a rise in serum hepatic transaminases concentrations.
Levels declined after two weeks, despite ongoing treatment [19]. In
a study of six patients, Hepburn et al demonstrated acute
hepatocellular damage and a fall in the functional metabolic
capacity of the liver (demonstrated by a reduction in caffeine
clearance) that was rapidly reversible on stopping treatment [20].
There are no published reports of fulminant hepatic failure
secondary to SbV treatment for NWCL. Elevated serum amylase
levels are very commonly associated with SbV administration.
Gasser et al showed 48 out of 49 patients receiving standard SbV
had elevated amylase levels [21]. However, clinical pancreatitis is
rare and severe or fatal pancreatitis extremely rare [22].
Electrocardiogram changes have been described to occur in
50% of patients receiving standard parenteral SbV treatment for
NWCL, although cardiac toxicity with tachyarrhythmias is most
likely limited to patients with pre-existing cardiovascular pathology
[13,19,23–25].
Serious adverse events due to SbV are rare, and deaths are very
rare. When serious events do occur, they are most often due to
cardiac arrhythmias or pancreatitis.
Further data on the toxicity of SbV are available from clinical
trials where it has been used to treat visceral leishmaniasis (VL) in
African countries. Higher rates of toxicity are seen with higher
doses of parenteral SbV. Bryceson et al attempted to treat ten cases
of VL in Kenya with 60 mg/kg/day of SbV, administered in three
divided doses, but this regimen was modified or abandoned in six
of the cases due to suspected toxicity [26]. However, it is
inappropriate to compare treatment data for patients with
systemic VL in Africa and patients with cutaneous-limited disease
in the UK.
In NWCL-endemic countries, centres may both be familiar with
managing the condition and have limited resources and therefore
parenteral SbV treatment is usually ambulatory, with hospitalisa-
tion often only restricted to a small percentage of patients with co-
morbidities or experiencing complications [13]. This is contrary to
many centres treating imported NWCL in non-endemic, resource-
rich settings, where many clinicians follow the recommendations
of Davidson, who advocated inpatient treatment, and monitoring
with twice-weekly blood tests and electrocardiograms. Davidson
recommended suspending treatment for 1–2 days when liver
enzymes reached more than ten times the normal level, amylase
three times the normal level, the QTc interval is prolonged to
greater than 500 ms or in the event of a cardiac arrhythmia.
Davidson’s recommendations were based on the limited amount of
data available on SbV toxicity and were therefore not strictly
evidence-based, giving arbitrary thresholds for treatment suspen-
sion [23].
In contrast, in the 2003 study, Lawn et al found SbV toxicity to
be of little clinical significance [19]. Therefore since 2003,
treatment for NWCL at HTD is now provided in an outpatient
setting, provided that the patient is in good general health, less
than 65 years old, and with no known renal, hepatic or cardiac
disease. Outpatient care was standardised with the development of
a protocol-driven Integrated Care Pathway (ICP). A copy of the
HTD ICP can be found in the Supporting Information (Protocol
S1). A prospectively maintained patient database of patients with
NWCL has been kept at our centre since the introduction of the
ICP, and it is from this database that this study has been
conducted. Since 2003, the HTD has treated up to 20 cases a year
of NWCL with parenteral SbV. Cases are identified either when
patients self-present to the HTD returned travellers’ walk-in clinic
or are referred to our centre by general practices, dermatology
clinics and military hospitals from across the UK.
This retrospective survey had three aims. The first was to
determine the toxicity of SbV, when administered at 20 mg/kg/
day for 3–4 weeks. This was done both by examining liver, renal
and bone marrow function blood tests taken throughout the course
Author Summary
Sodium stibogluconate (SbV), a pentavalent antimonial,
administered parenterally, is the recommended treatment
for South American cutaneous leishmaniasis, caused by
Leishmania Viannia, which is a neglected disease that
affects many people resident in Central and South
America, as well as travellers to the areas. Antimonials
have been used for the treatment of leishmaniasis since
the 1930s. We report the toxicity experienced by a series of
NWCL patients receiving SbV in a resource-rich setting.
This study also evaluates administration of the drug to
patients without admitting them to hospital. The admin-
istration of parenteral SbV was associated with myelosup-
pression, derangement of markers of liver function and
prolongation of the QT interval on electrocardiography,
although these effects were not found to be associated
with adverse clinical events, and the majority of doses of
SbV were administered without cause for hospital admis-
sion. Our data shows that parenteral SbV treatment may
be provided with reduced monitoring for toxicity than is
currently done, and on an outpatient-basis, without
endangering safety. Such practice, with reduced demands
on local finances and the healthcare workforce, would be
desirable in more resource-limited settings.
Toxicity SbV in New World Cutaneous Leishmaniasis
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tively reported by the patients in a daily structured questionnaire.
Patients were asked at every treatment if they had symptoms of
nausea, myalgia, skin rashes, abdominal pain and/or malaise. The
second aim of this study was to determine adherence to the
treatment protocol outlined in the ICP by both patients and staff.
The ICP recording tool was examined to see whether patients
observed the requirement to attend daily for drug administration.
The third aim was to determine the efficacy of delivering
treatment on an outpatient basis in British patients. There may
be differences in responses to treatment and experienced effects by
different ethnic group. Prior to the current report, outpatient
treatment with parentral SbV in the UK has only been reported in
a study on 13 marines [17].
Methods
Ethics Statement
Our institutional review board (IRB) assessed the project and
ruled that this project was a retrospective review and a clinical
audit and exempted the author group from requiring formal
approval. All patient data analysed was anonymised, with patient-
identifying information removed, obviating the need for patient
consent.
Case Definition
Patients were either diagnosed with NWCL after presenting to
the HTD walk-in clinic, or were referred to our centre by another
hospital or general practitioner. Lesions indicative of NWCL were
biopsied for microscopy with Romanovsky type-staining (Rapid
Field’s), culture with modified Novy-McNeal-Nicolle medium and
polymerase chain reaction (PCR) for leishmania DNA. Specimens
were also examined histologically.
A case of NWCL requiring parenteral SbV was defined as a
typical lesion(s) in a returned traveler from an endemic country in
Latin America with confirmation of leishmania infection in at least
one laboratory modality and either identification of L.viannia DNA
on PCR or identification of a ‘complex’ case with multiple or large
lesions or lesions involving the face, a joint, or the lymphatic
system. Patients were offered outpatient treatment on the ICP if
they meet the following criteria: under 65 years of age, able to
attend daily; no pre-existing cardiac or renal condition; normal full
blood count, urea and electrolytes and liver function tests; and
normal electrocardiogram with corrected QT interval less than
421 milliseconds.
We identified all patients who received a course of parenteral
SbV for NWCL on the ICP at our centre from April 2003 (when
the ICP was introduced) until September 2008 from a prospec-
tively maintained clinical research database.
Description of Management of NWCL on the ICP
Patients travelled to the hospital daily from home or a local
hotel. Treatment was for 21 days, which was extended up to 28
days, at the discretion of the attending consultant, if lesion healing
was unsatisfactory. Treatment was administered, the lesion was
assessed and adverse effects were documented, in accordance with
the ICP protocol (summarised in Table 1, complete copy of the
ICP in Supporting Information (Protocol S1)), which was printed
in a booklet that also served as a data-recording tool. The nursing
staff reviewed and dressed each lesion daily, supplemented by a
more detailed weekly inspection. The dose of SbV (PentostamH,
Wellcome, Brentford, Middlesex, UK) was 20 mg/kg, with no
upper limit, diluted in 100 ml of 0.9% saline and administered
over 30 minutes via a peripheral venous cannula that was changed
every third day. Temperature, pulse and respiratory rates, and
blood pressure were measured before, during and after treatment.
Nursing staff documented daily if the patient was experiencing
myalgia, a skin rash, nausea, malaise or abdominal pain. The team
duty doctor was informed if there was any adverse event. Each
patient was also medically reviewed every third day, and a full
blood count, serum electrolytes, liver function tests and a 12-lead
electrocardiogram obtained. Serum amylase was only checked if
pancreatitis was clinically suspected. Interruption of treatment was
at the discretion of the attending consultant.
Data Collection and Statistics
A retrospective analysis was performed on the case notes, the
ICP case recording tool and laboratory results for each patient.
The reference ranges of the hospital’s laboratories were utilised as
the normal ranges for serum concentrations of haemoglobin (11.5–
15.5 g/dL), lymphocytes (1.20–3.65610
9/L), eosinophils (0.0–
0.4610
9/L), platelets (150,000–400,000/mL), creatinine (49–
92 mmol/L), bilirubin (6–23 mmol/L), and alanine transaminase
(10–35 iu/L). Patients’ symptoms during treatment had been
recorded prospectively, using the daily screening questionnaire.
The case notes were examined for clinical events suggestive of
disordered haemostasis, immune suppression or liver failure. We
examined the ICP for the incidence of prolongation of the QTc
(over 420 ms), as recorded by the clinicians reviewing the ECGs at
time of treatment. The ECGs themselves were not analysed in this
Table 1. The ‘Integrated Care Pathway (ICP)’ framework for patient monitoring.
Day of treatment assessment performed Assessment or intervention Member of staff performing assessment
Pre-treatment, 1, 4, 7, 10, 13, 16, 19, 21, (24), (28) Full blood count, urea and electrolytes, liver
function tests, electrocardiogram
Doctor or nurse, results reviewed by doctor
Daily Lesion condition and dressing Nurse
1, 7, 13, 21, (28) Lesion location, size, grade, floor condition,
surrounding skin condition, exudate, odour,
pain, infection status and plan for lesion dressing
Nurse
Daily Screening questionnaire for patient-experienced effects Nurse
Daily Blood pressure, temperature, respiratory rate and
heart rate before, during and after treatment
Nurse
Pre-treatment, 1, 4, 7, 10, 13, 16, 19, 21, (24), (28) Patient review Doctor
See Supporting Information (Protocol S1) for a complete copy of the ICP record-of-care proforma.
doi:10.1371/journal.pntd.0001688.t001
Toxicity SbV in New World Cutaneous Leishmaniasis
www.plosntds.org 3 June 2012 | Volume 6 | Issue 6 | e1688study, as this aspect of toxicity has been reported in previous
studies [19,24,25].
Repeated measures analyses-of-variance (ANOVAs) was per-
formed on the haematological and biochemical laboratory values
measured prior to initiation of treatment and on days four, seven, 10,
13, 16, 19 and 21 of treatment. Pairwise differences were calculated
for combinations for each of the dates (multiple comparison corrected
(Bonferroni) analysis) and p-values were calculated. The level of the
tests for significance was 0.05. Data were analysed by SPSS for
windows version 16.0 (SPSS Inc., IBM, Somers, New York, USA).
Results
Clinical Features of Patients
Sixty-seven patients (50 male) with NWCL were treated using
the ICP between April 2003 and September 2008. The mean age
was 30 years (range 17–61 years). None of the patients had human
immunodeficiency virus infection (routine screening was not
performed), and none had a significant co-morbid disease. Belize
was the most common country of acquisition (32/67, 47.7%) and
25/67 patients were serving in the British Armed Forces and had
acquired their CL during military training in the jungles of Belize.
Other countries of acquisition were Peru (7/67), Bolivia (7/67),
Guyana (5/67), Costa Rica (4/67), Brazil (3/67), Ecuador (3/67),
Mexico (2/67), Guatemala (1/67) and Columbia (1/67). Of the 67
patients, 51 had infection with L.viannia, 12 had infection with
L.mexicana complex, in one patient insufficient protozoal DNA was
obtained to determine the infecting species, in two patients PCR
was not performed and in one no DNA was found. Systemic
therapy was given to the patients with L.mexicana complex
infections as there were facial lesions (4/12), large or deep lesions
(4/12), multiple lesions (3/12) or extensive lymphadenopathy (1/
12). One third of all patients treated (24/67) had more than one
cutaneous lesion. Lesions were most common on exposed areas
(distal to the elbows, distal to the knees, or over the head and neck
(85/112 of the total number of lesions). There was sporotrichoid
spread or lymphadenopathy in lymph nodes adjacent to the skin
lesions, palpable on clinical examination, in 19/67 of the cases. No
patients had clinical evidence of mucocutaneous infection at the
time of treatment. Two of the 67 patients had received prior
treatment for their NWCL: one patient had received 21 days of
intramuscular SbV while in Argentina, the second had received
parenteral SbV, suspended after 12 doses due to deranged liver
function, and amphotericin, stopped due to an allergic reaction, at
another UK hospital.
Adherence to Treatment
Table 2 documents the number of daily treatments the patients
received. 61/67 (91.0%) received at least 20 days treatment. All
causes for interruptions to treatment are documented in Table 3.
12/67 patients (17.9%) had disrupted treatment due to toxicity or
experienced effects. Patient adherence to the treatment protocol
was high, with only two patients failing to attend for six days in
total. Only one treatment was omitted due to nursing error.
Table 2. Total number of SbV doses received by each of the
67 patients.
Total number of treatment
doses administered
Number (%)
of patients
9 1/67 (1.5)
12 1/67 (1.5)
13 1/67 (1.5)
16 1/67 (1.5)
19 2/67 (3.0)
20 5/67 (7.5)
21 43/67 (64.2)
22 3/67 (4.5)
24 1/67 (1.5)
25 1/67 (1.5)
28 7/67 (10.4)
Insufficient data 1/67 (1.5)
doi:10.1371/journal.pntd.0001688.t002
Table 3. Reasons for treatment suspensions and omissions.
Patient Reason for drug omission No. of days treatment was suspended
A Platelet count dropped to 14610
9/L 7
B Abdominal pain, nausea, myalgia 1
C Urticarial rash 2
D Vomiting and abdominal pain 1
E Fevers, rigors and headache 4
F Fevers and unwell 2
G Patient did not attend 5
H Nursing error 1
I Neutrophil count dropped to 0.83610
9/L 4
J Patient did not attend 1
K QTc prolonged to 524 ms 1
L Patient developed a MSSA bacteraemia Treatment terminated day 14
M ALT elevated at 447 iu/L 10
N ALT elevated at 492 iu/L 5
O Developed chest pain during treatment Half of dose omitted
doi:10.1371/journal.pntd.0001688.t003
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staff failed to compensate with additional treatment days at the
end of expected treatment.
Treatment Response
Additional intra-lesional SbV treatment, to assist primary lesion
healing, was administered to two patients while they underwent
the ICP, and to a further five patients at outpatient follow-up. One
of these patients was also given a course of allopurinol to aid
healing. These patients are considered presumptive parenteral
SbV treatment failures. 19/67 (28.4%) patients failed to attend a
follow-up appointment following the completion of treatment on
the ICP, often, in the case of military personnel, due to
redeployment abroad. Of the 48 patients not lost to follow-up,
29 (60.4%) and 38 (79.2%) patients had lesions that had
completely re-epithelialised within two and six months of
completing treatment with parenteral SbV respectively (and had
not required additional intra-lesional treatment). No patients have
reported with re-occurrence of cutaneous disease. Only one of the
44 cases infected with L.viannia developed MCL - 16 months after
completing the ICP, the DNA of L.viannia was detected following a
nasal biopsy to investigate persistent nasal stuffiness.
Treatment Toxicity
The mean weight of the female patients was 62 kg and mean
daily dose of SbV given was 1230 mg (range 1000 mg–1600 mg).
The mean weight for male patients was 78 kg and mean daily dose
of SbV given was 1560 mg (range 1300 mg–1800 mg). The study
did not identify an obvious association between patients receiving
a larger dose of SbV per day (31/67 patients received over
1500 mg/SbV/day) and the toxicity experienced.
There was a significant drop in lymphocyte counts between
pre-treatment levels and all subsequent lymphocyte levels
throughout the course of treatment (Figure 1). The median
lymphocyte count prior to treatment was 2.06610
9/L, falling to
1.57610
9/L four days after initiating treatment, a reduction of
0.53610
9/L, confidence Intervals (CI) 0.29610
9/L to 0.76610
9/
L, p,0.001 (repeated measures ANOVA). There was no further
significant change in the lymphocyte count, between days seven
and 19, after the initial reduction. Although the median
lymphocyte count never dropped below the lower end of normal
reference range of 1.2610
9/L. There were no documented events
of opportunistic infections in our patient group. NWCL was not
associated with an eosinophilia (mean eosinophil count pre-
treatment 0.25610
9/L), nor did the eosinophil count change
during treatment.
There was a small but significant drop in the median platelet
count in response to treatment (Figure 2). The median platelet
count decreased from 252,000/mL before the initiation of
treatment to 222,000/mL on the fourth day (a fall of 31,000/
mL, CI 16,000/mL to 46,000/mL, p,0.001). There was no further
significant fall in the platelet counts between days seven to 19.
Throughout treatment, the median platelet count never dropped
below the lower end of normal reference range of 150,000/mL,
and there were no documented events of bleeding. However, two
patients became thrombocytopaenic, (with platelet counts of
32,000/mL and 54,000/mL respectively), both after ten days of
treatment. There were no bleeding events, treatment was
suspended for seven days in the former patient and continued
in the latter, and in both the count recovered to within the
normal reference range. There was a small fall in mean
haemoglobin concentration by day 19 (1.0 g/L, CI 0.59 to
1.43, p,0.001).
Serum alanine transaminase (ALT) concentrations rose signif-
icantly after starting treatment, with considerable individual
variability (Figure 3). The peak median rise was 107 iu/L by
day 13 (CI 52 iu/L to 161 iu/L, p,0.001). The levels decreased
thereafter, despite ongoing treatment, though this was not
significant. In one patient, the ALT rose to 492 iu/L by day 10,
and treatment was suspended for five days. The level had declined
to 278 iu/L by day 19. None of the patients developed a clinically
apparent hepatitis. Serum bilirubin and creatinine levels did not
rise during treatment. Serum amylase levels were not routinely
checked in the patient group. No patient in the group was
clinically suspected of having pancreatitis. The peak incidence for
reported abdominal pain was on day 18 of treatment (in five of the
Figure 1. Box-and-whisker plot of the lymphocyte counts of
patients plotted against duration of treatment with sodium
stibogluconate (SbV). The group median (squares) fell significantly
from its baseline by the first subsequent measurement, four days after
initiating treatment (p,0.001). It then plateaued, with no further
significant change. Outliers are depicted by circles, extremes are
depicted by hashes.
doi:10.1371/journal.pntd.0001688.g001
Figure 2. Box-and-whisker plot of the platelet counts of
patients plotted against duration of treatment with sodium
stibogluconate (SbV). The group median (squares) fell significantly
from its baseline by the first subsequent measurement, four days after
initiating treatment (p,0.001). It then plateaued, with no further
significant change. Outliers are depicted by circles, extremes are
depicted by hashes.
doi:10.1371/journal.pntd.0001688.g002
Toxicity SbV in New World Cutaneous Leishmaniasis
www.plosntds.org 5 June 2012 | Volume 6 | Issue 6 | e168855 patients questioned), some of which may have represented
symptomatic hyperamylasemia.
QTc prolongation (range 422–524msec) occurred in nine out of
67 patients, on days four to 19 of treatment. There were no
documented events of clinically suspected tachyarrhythmias.
The responses to the symptom questionnaire are summarised in
Figure 4. Out of a total of 66 patients for whom there was
sufficient data, 63 (95.5%) reported at least one adverse reaction.
The timing for peak incidences for side effects was: day 15 for skin
rashes (11/59 of patients whose response was recorded), day 18 for
abdominal pain (5/55 patients), day 19 for nausea (9/56 patients),
day 19 for general malaise (20/56 patients) and day 21 for myalgia
(28/47 patients).
Although myalgia was common, no patients were suspected to
have rhabdomyolysis. Creatine kinase was not routinely checked.
For most patients these side effects were mild and transient, and
resolved soon after completion of treatment. One patient, who had
a history of eczema, had worsening eczema during treatment,
which persisted for six months. One patient developed pelvic pain
that persisted for four months after treatment finished, but no
pelvic pathology was found on investigation.
3/67 patients required one night’s hospital admission for drug-
related side effects (one for myalgia, one for vomiting, and one for
pyrexia). This was out of a total of 1407 doses of drug
administered. One patient had their treatment terminated on
day 14 for a methicillin-sensitive Staphylococcus aureus bacteraemia
secondary to an infected cannula site, which responded to
intravenous antibiotics. One patient was admitted for three nights
within a week of completing treatment with abdominal pain,
vomiting, headache and a temperature that settled with supportive
treatment. One patient was admitted for six nights during his
treatment as he was of no fixed abode. In total, for the 67 patients
treated on the ICP, 1381 bed days were saved.
Discussion
This study has demonstrated that NWCL can be managed
successfully on an outpatient basis, with good clinical outcome,
patient adherence to the treatment regime, and staff adherence to
the ICP protocol. The majority of doses were administered
without complication, and overall treatment was well tolerated
without major toxicity. However, almost all patients experienced
the adverse symptoms associated with a course of parenteral
sodium stibogluconate. The use of an outpatient regime was
preferred by patients and represents a major financial saving.
Figure 3. Box-and-whisker plot of serum alanine transaminase
concentrations against duration of treatment with sodium
stibogluconate (SbV). The group median (squares) rose significantly
by day 10 after initiation of treatment (p,0.001). Outliers are depicted
by circles, extremes are depicted by hashes.
doi:10.1371/journal.pntd.0001688.g003
Figure 4. Percentage of patients reporting side-effects on each day of treatment with sodium stibogluconate (SbV).
doi:10.1371/journal.pntd.0001688.g004
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protocol enhanced the quality and quantity of relevant data that
could be surveyed and analysed. The rigorous laboratory
monitoring of patients on SbV demonstrated that there were
falls in the lymphocyte, platelet and haemoglobin counts during
the course of treatment, but that this haematological suppression
was not clinically significant, despite a steep drop in platelet
counts in two patients. It is not possible to predict which patients
will experience thrombocytopaenia with SbV: we found no
relationship between the initial platelet count of individuals
receiving treatment and subsequent decreases in platelet count.
Serum alanine transaminase became elevated, but in a transient
and predictable manner, and without detectable adverse effect.
Monitoring of bilirubin levels and renal function was demon-
strated to be unnecessary. Repeated electrocardiography on
patients undergoing treatment did demonstrate transient QTc
prolongation in some patients, but in this cohort this did not
result in clinically apparent cardiac arrhythmias. We cannot
exclude the possibility that some patients experienced silent
arrhythmias that might have become apparent with prolonged
recordings.
We propose that, at appropriate treatment centres, all patients
with NWCL under the age of 65 years, able to attend daily, with
no pre-existing cardiac or renal condition and with a normal full
blood count, serum electrolyte and liver function profile and an
electrocardiogram with a normal QTc interval, be considered for
day-case treatment with a treatment protocol. Our data shows that
not all patients require twice-weekly biochemical and electrocar-
diographic monitoring: in healthy low-risk individuals, asymptom-
atic lymphopaenia, thrombocytopaenia, hepatic transaminitis,
hyperamylasaemia and QTc prolongation may well be of no
clinical significance and resolve despite continuation of treatment.
It could be argued that monitoring for these toxic effects
sometimes engendered anxiety, in both the clinician and the
patient, and may have resulted in unnecessary temporary
suspension of treatment. This may have delayed eradication of
infection in these patients, thereby increasing the time to healing
and the risk of lesion reoccurrence and parasite dissemination. We
propose that monitoring in asymptomatic patients should be
limited to only a repeat full blood count, liver function tests
amylase on day 10 of SbV-treatment, where the clinician may
consider suspension of treatment for a maximum of seven days if
the platelet count is less than 50610
9/L or the ALT is ten times or
more the upper limit of normal. Monitoring with electrocardio-
grams of young otherwise healthy individuals with no history of
heart disease is not necessary if the antimony dose does not exceed
20 mg/kg/day, as previously recommended by Chulay and
colleages [25].
During a course of parenteral SbV, the emphasis should be on
symptomatic relief for patient-described toxicity (most patients
experienced at least myalgia by the third week of treatment).
Before starting a course of SbV patients should be advised that
they are likely to experience at least one of nausea, myalgia,
malaise, a skin rash and/or abdominal pain and should be
reassured that these symptoms are, on the whole, benign and
transient. There is anecdotal evidence that administering
glucocorticoids in patients receiving parenteral SbV may provide
symptomatic relief, although there is insufficient evidence to
justify co-administration of glucocorticoids with SbV, unless it is
being used in the management of urticaria [27]. Future studies
on SbV should be directed towards optimising both pharmaco-
logical and non-pharmacological management of patient’s
symptoms.
Management of NWCL as an outpatient may ease the burden
of treatment to staff, patients and health economies. Local hotel
accommodation was arranged if daily commuting from home was
not feasible for the patients. This remained a cheaper option than
hospital admission.
SbV is an effective drug against L.viannia CL, and for now is
likely to remain the mainstay of its treatment in United Kingdom
treatment centres. However, despite our recommendations that
the use of SbV in NWCL does not require as close monitoring as
previously felt necessary, it remains a drug with appreciable
transient and mild side effects. Furthermore, the development of a
novel treatment for NWCL that could be administered orally
rather than parenterally and/or for a shorter period than the
current three weeks would be preferable and better suited for more
resource-poor settings than the UK. Miltefosine is an oral
preparation and is currently under evaluation for the treatment
of NWCL. It is emerging as a treatment option for CL in South
America, where rates of lesion healing achieved with SbV are
lower than in UK centres. Unfortunately, the side-effect profile of
miltefosine in not insignificant and adverse effects occur with a
similar frequency in miltefosine administration as to SbV, albeit of
a different nature, with vomiting, nausea and diarrhoea most
commonly observed. Two recent clinical trials, each of 60 patients
receiving miltefosine, reported no serious adverse events [28,29].
The need remains for new drug development for one of the
world’s most neglected diseases.
Limitations
This case series is a retrospective review and so may be less
rigorous than a prospective study, although the use of the
‘Integrated Care Pathway’ protocol in the patients’ management
and its recording tool has enhanced the quality of our data. As
would be expected in any retrospective review, some data was
inadequate and in particular we had only limited data on time to
lesion healing. The reporting of side effects was subject to bias
from both the patient and healthcare provider and ideally the
efficacy and toxicity of a drug should be studied in a double-
blind randomized control trial as opposed to an observational
study. Although our case series of 67 NWCL patients is the
largest produced by a UK centre, it remains a relatively small
study.
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